Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "recombinant protein" wg kryterium: Temat


Wyświetlanie 1-14 z 14
Tytuł:
A systematic investigation of the stability of green fluorescent protein fusion proteins
Autorzy:
Janczak, Monika
Bukowski, Michał
Górecki, Andrzej
Dubin, Grzegorz
Dubin, Adam
Wladyka, Benedykt
Powiązania:
https://bibliotekanauki.pl/articles/1038973.pdf
Data publikacji:
2015
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
crystallography
fusion protein
recombinant protein
toxin-antitoxin system
Opis:
X-ray crystallography provides important insights into structure-function relationship in biomolecules. However, protein crystals are usually hard to obtain which hinders our understanding of multiple important processes. Crystallization requires large amount of protein sample, whereas recombinant proteins are often unstable or insoluble. Green fluorescent protein (GFP) fusion is one of the approaches to increase protein synthesis, solubility and stability, facilitating crystallization. In this study we analyze the influence of the linker length, composition and the position of GFP relative to the fusion partner on the fusion protein production and stability. To this end, multiple constructs of enzymatically impaired variant of PemKSa toxin from Staphylococcus aureus CH91 fused to GFP were generated. Fusion protein production in Escherichia coli was evaluated. The proteins were purified and their stability tested. PemKSa-α14aa-GFP fusion provided best production and stability. Obtained results demonstrate the importance of optimization of fusion protein construct, including linker selection and the order of fusion partners, in obtaining high quantities of stable protein for crystallization.
Źródło:
Acta Biochimica Polonica; 2015, 62, 3; 407-411
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Molecular cloning of the OMP19 gene from Brucella melitensis strain H38 and its antigenicity compared to that of commercial OMP19
Autorzy:
Uslu, A.
Sanioglu Golen, G.
Agah Tekindal, M.
Sakmanoglu, A.
Sayın, Z.
Denizli, O.
Gok, A.
Erganis, O.
Powiązania:
https://bibliotekanauki.pl/articles/16630377.pdf
Data publikacji:
2022
Wydawca:
Polska Akademia Nauk. Czasopisma i Monografie PAN
Tematy:
rOMP19 antigen
Brucella melitensis
recombinant protein
Opis:
Brucellosis is a worldwide zoonosis, that can still be classified as endemic despite its ancient origins which causes economic losses and public health problems. Although effectively controlled by vaccination in animals, there is currently no vaccine for use in humans. Outer Membrane Proteins (OMP) that play an active immunogenic and protective role in the Brucellae family. OMP19 is present in all Brucella species as a surface antigen and is a potent immunogen responsible for Brucellosis intracellular infection. For this reason, the study was aimed to be used safely as a potential recombinant vaccine candidate against all Brucella infections, especially in humans and pregnant animals. This study evaluated a Brucella lipoprotein antigen, i.e. 19 kilodalton (kDa) outer membrane protein (OMP19), which was amplified and cloned into the pETSUMO vector system. The immunogenic power of the purified recombinant OMP19 antigen against brucellosis was compared with that of OMP19 (Raybiotech Inc, USA) in a mouse model and the obtained rOMP19 antigen was found to be similar to the commercially available recombinant protein.
Źródło:
Polish Journal of Veterinary Sciences; 2022, 25, 4; 561-569
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Expression level of Ubc9 protein in rat tissues.
Autorzy:
Gołębiowski, Filip
Szulc, Aneta
Sakowicz, Monika
Szutowicz, Andrzej
Pawełczyk, Tadeusz
Powiązania:
https://bibliotekanauki.pl/articles/1043384.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
Ubc9
rat
recombinant protein
tissue distribution
Opis:
Ubc9 is a homologue of the E2 ubiquitin conjugating enzyme and participates in the covalent linking of SUMO-1 molecule to the target protein. In this report we describe a simple and efficient method for obtaining pure human recombinant Ubc9 protein. The purified Ubc9 retained its native structure and was fully active in an in vitro sumoylation assay with the promyelocytic leukaemia (PML) peptide as a substrate. In order to better understand the physiology of Ubc9 protein we examined its levels in several rat tissues. Immunoblot analyses performed on tissue extracts revealed quantitative and qualitative differences in the expression pattern of Ubc9. The Ubc9 protein was present at a high level in spleen and lung. Moderate level of Ubc9 was detected in kidney and liver. Low amount of Ubc9 was observed in brain, whereas the 18 kDa band of Ubc9 was barely visible or absent in heart and skeletal muscle. In heart and muscle extracts the Ubc9 antibodies recognized a 38 kDa protein band. This band was not visible in extracts of other rat tissues. A comparison of the relative levels of Ubc9 mRNA and protein indicated that the overall expression level of Ubc9 was the highest in spleen and lung. In spleen, lung, kidney, brain, liver and heart there was a good correlation between the 18 kDa protein and Ubc9 mRNA levels. In skeletal muscle the Ubc9 mRNA level was unproportionally high comparing to the level of the 18 kDa protein. The presented data indicate that in the rat the expression of the Ubc9 protein appears to have some degree of tissue specificity.
Źródło:
Acta Biochimica Polonica; 2003, 50, 4; 1064-1073
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cloning and purification of functionally active Fas ligand interfering protein (FIP) expressed in Escherichia coli
Autorzy:
Wisniewski, Pawel
Master, Adam
Kaminska, Bozena
Powiązania:
https://bibliotekanauki.pl/articles/1040813.pdf
Data publikacji:
2008
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
Fas ligand
interfering molecules
recombinant protein purification
Fas
apoptosis
Opis:
This report presents purification and characterization of the extracellular domain of rat Fas protein, called FIP (FasL interfering protein), expressed as inclusion bodies in Escherichia coli. FIP was extracted from the inclusion bodies, solubilized with 8 M urea, purified by a single-step immobilized metal ion (Ni2+) affinity chromatography and refolded. SDS/PAGE and mass spectrometry analysis of the purified protein verified its purity. Fluorescence spectrum analysis showed that the refolding procedure caused structural changes which presumably might have led to oligomerization. The purified FIP has biological activities: it binds specifically soluble Fas ligand and protects human Jurkat lymphocytes against FasL-dependent apoptosis. This efficient procedure of FIP expression in E. coli and renaturation may be useful for production of therapeutically important proteins.
Źródło:
Acta Biochimica Polonica; 2008, 55, 1; 51-56
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Expression level of adenosine kinase in rat tissues. Lack of phosphate effect on the enzyme activity.
Autorzy:
Sakowicz, Monika
Grdeń, Marzena
Pawełczyk, Tadeusz
Powiązania:
https://bibliotekanauki.pl/articles/1044105.pdf
Data publikacji:
2001
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
rat
recombinant protein
phosphate
tissue distribution
adenosine kinase
Opis:
In this report we describe cloning and expression of rat adenosine kinase (AK) in Esccherichaia coli cells as a fusion protein with 6xHis. The recombinant protein was purified and polyclonal antibodies to AK were generated in rabbits. Immunoblot analysis of extracts obtained from various rat tissues revealed two protein bands reactive with anti-AK IgG. The apparent molecular mass of these bands was 48 and 38 kDa in rat kidney, liver, spleen, brain, and lung. In heart and muscle the proteins that react with AK antibodies have the molecular masses of 48 and 40.5 kDa. In order to assess the relative AK mRNA level in rat tissues we used the multiplex PCR technique with β-actin mRNA as a reference. We found the highest level of AK mRNA in the liver, which decreased in the order kidney >spleen >lung >heart >brain >muscle. Measurement of AK activity in cytosolic fractions of rat tissues showed the highest activity in the liver (0.58 U/g), which decreased in the order kidney >spleen >lung >brain >heart >skeletal muscle. Kinetic studies on recombinant AK as well as on AK in the cytosolic fraction of various rat tissues showed that this enzyme is not affected by phosphate ions. The data presented indicate that in the rat tissues investigated at least two isoforms of adenosine kinase are expressed, and that the expression of the AK gene appears to have some degree of tissue specificity.
Źródło:
Acta Biochimica Polonica; 2001, 48, 3; 745-754
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Oral Lyme disease vaccine
Autorzy:
Urbanowicz, A.
Lewandowski, D.
Figlerowicz, M.
Powiązania:
https://bibliotekanauki.pl/articles/80064.pdf
Data publikacji:
2014
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
Lyme disease
Borrelia burgdorferi
vaccine
prophylactic vaccination
recombinant protein
OspC protein
OspA protein
patent
Źródło:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2014, 95, 4
0860-7796
Pojawia się w:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Elastin-like polypeptides-alternative way of recombinant protein purification
Autorzy:
Kowalczyk, T.
Hnatuszko-Konka, K.
Gerszberg, A.
Kononowicz, A.K.
Powiązania:
https://bibliotekanauki.pl/articles/81055.pdf
Data publikacji:
2013
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
conference
molecular biology
biotechnology
protein expression
protein extraction
purification
elastin-like polypeptide
biopolymer
recombinant protein purification
Źródło:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2013, 94, 3
0860-7796
Pojawia się w:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Environmental and recombinant microorganisms for biopharmaceuticals production
Autorzy:
Matejczyk, M.
Powiązania:
https://bibliotekanauki.pl/articles/403071.pdf
Data publikacji:
2014
Wydawca:
Politechnika Białostocka. Oficyna Wydawnicza Politechniki Białostockiej
Tematy:
bacteria
yeast
recombinant protein production (RPP)
biopharmaceuticals
bakteria
drożdże
produkcja rekombinowanego białka (RPP)
biopreparat
Opis:
Current, very fast development of genetic engineering and protein engineering (main segments of modern biotechnology) is a good way for commercially production of proteins, which benefit biopharmaceutical, the enzyme and agricultural industries. These products augment the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics. Proteins with biopharmaceutical application are mainly clinical reagents, vaccines and drugs. During the last decade, the pharmaceutical biotechnology represents the fastest growing segment in the biotechnology sector. Production of recombinant proteins for use as pharmaceuticals, is a multi-billion dollar industry. One third of the biopharmaceuticals has come from microorganisms, such as Escherichia coli and yeast. The selection of expression systems depends on the size and biochemical status of proteins. Large proteins and proteins that require glycosylation are usually expressed in a mammalian cells, fungi or the baculovirus system. Smaller proteins are produced by prokaryotic cells. There are some very useful advantages for prokaryotic recombinant expression systems: it is easy of culture, very rapid cell growth with possibility of IPTG expression induction and quite simple product purification. On the other hand, for very large proteins, for S-S rich proteins and proteins which require post-translational modifications, bacteria, usually E. coli strains are not robust system. Better are yeasts with very popular species Saccharomyces cerevisiae and Pichia pastoris. This article presents the current application of microbes as production platforms for recombinant proteins and its genetic engineering for the use as biopharmaceuticals.
Źródło:
Budownictwo i Inżynieria Środowiska; 2014, 5, 1; 15-21
2081-3279
Pojawia się w:
Budownictwo i Inżynieria Środowiska
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Expression of the gene encoding blood coagulation factor VIII without domain B in E. coli bacterial expression system
Autorzy:
Mazurkiewicz-Pisarek, Anna
Mazurkiewicz, Alina
Mikiewicz, Diana
Baran, Piotr
Ciach, Tomasz
Powiązania:
https://bibliotekanauki.pl/articles/16706242.pdf
Data publikacji:
2023
Wydawca:
Polska Akademia Nauk. Czasopisma i Monografie PAN
Tematy:
factor VIII
hemophilia type A
recombinant coagulation factor VIII
prokaryotic expression system
E. coli
recombinant protein production system
Opis:
In this article, we have demonstrated the feasibility of generating an active form of recombinant blood coagulation factor VIII using an E. coli bacterial expression system as a potential treatment for hemophilia type A. Factor VIII (FVIII), an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. So far, all available recombinant FVIII formulations have been produced using eukaryotic expression systems. Mammalian cells can produce catalytically active proteins with all the necessary posttranslational modifications. However, cultivating such cells is time-consuming and highly expensive, and the amount of the obtained product is usually low. In contrast to eukaryotic cells, bacterial culture is inexpensive and allows the acquisition of large quantities of recombinant proteins in a short time. With this study, we aimed to obtain recombinant blood coagulation factor VIII using the E. coli bacterial expression system, a method not previously explored for this purpose. Our research encompasses the synthesis of blood coagulation factor VIII and its expression in a prokaryotic system. To achieve this, we constructed a prokaryotic expression vector containing a synthetic factor VIII gene, which was then used for the transformation of an E. coli bacterial strain. The protein expression was confirmed by mass spectrometry, and we assessed the stability of the gene construct while determining the optimal growth conditions. The production of blood coagulation factor VIII by the E. coli bacterial strain was carried out on a quarter-technical scale. We established the conditions for isolation, denaturation, and renaturation of the protein, and subsequently confirmed the activity of FVIII.
Źródło:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2023, 104, 3; 247-262
0860-7796
Pojawia się w:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Application of selected medicinal plants such as chamomile and kalanchoe from in vitro culture for production of recombinant proteins
Autorzy:
Bandurska, K.
Krupa, P.
Powiązania:
https://bibliotekanauki.pl/articles/951330.pdf
Data publikacji:
2015
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
conference
medicinal plant
chamomile
Matricaria chamomilla
kalanchoe
Kalanchoe daigremontiana
in vitro culture
recombinant protein
biopharmaceutical industry
Źródło:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2015, 96, 1
0860-7796
Pojawia się w:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant
Autorzy:
Kowalski, Michał
Brown, George
Bieniasz, Magdalena
Oszajca, Katarzyna
Chabielska, Ewa
Pietras, Tadeusz
Szemraj, Zofia
Makandjou-Ola, Eusebio
Bartkowiak, Jacek
Szemraj, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1040615.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
K2 domain of t-PA
thrombolytic and antithrombotic agents
thrombolysis
staphylokinase
recombinant protein
hirulog
antiplatelet activity
Opis:
To develop a more potent antithrombin agent with thrombolytic and antiplatelet properties, a new staphylokinase (SAK) variant was constructed. The kringle 2 domain (K2) of tissue type-plasminogen activator (t-PA) containing a fibrin-specific binding site (i), the RGD sequence (Arg-Gly-Asp) for the prevention of platelet aggregation (ii) and the antithrombotic agent - hirulog (iii) was assembled to the C-terminal part of recombinant staphylokinase (r-SAK). cDNA for the hybrid protein SAK-RGD-K2-Hirul was cloned into Pichia pastoris pPIC9K yeast expression vector. The introduction of K2 t-PA, the RGD sequence and hirulog into the C-terminus of r-SAK did not alter the staphylokinase activity. We observed a higher clot lysis potency of SAK-RGD-K2-Hirul as evidenced by a faster and more profound lysis of 125I-labeled human fibrin clots. The potency of thrombin inhibition by the hirulog C-terminal part of the recombinant fusion protein was almost identical to that of r-Hir alone. These results suggest that the SAK-RGD-K2-Hirul construct can be a more potent and faster-acting thrombolytic agent with better antithrombin and antiplatelet properties compared to r-SAK and SAK-RGD-K2-Hir.
Źródło:
Acta Biochimica Polonica; 2009, 56, 1; 41-53
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Biochemical and structural studies of plant circadian clock proteins
Autorzy:
Saini, R.
Szpotkowski, K.
Kozak, M.
Jaskolski, M.
Davis, S.J.
Powiązania:
https://bibliotekanauki.pl/articles/80840.pdf
Data publikacji:
2013
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
circadian clock
diurnal change
plant circadian clock
protein
multiple feedback loop
crystallization
recombinant fusion protein
early flowering
small angle X-ray scattering
protein-protein interaction
biochemical study
structural study
Źródło:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology; 2013, 94, 1
0860-7796
Pojawia się w:
BioTechnologia. Journal of Biotechnology Computational Biology and Bionanotechnology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Influenza virus hemagglutinin as a vaccine antigen produced in bacteria
Autorzy:
Sączyńska, Violetta
Powiązania:
https://bibliotekanauki.pl/articles/1039263.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
recombinant influenza hemagglutinin
recombinant influenza vaccine
subunit influenza vaccine
bacterial hemagglutinin
prokaryotic protein production
Opis:
Recombinant subunit vaccines based on hemagglutinin proteins produced in bacteria (bacterial HAs) are promising candidates for enhancing the supply of vaccines against influenza, especially for a pandemic. Over 20 years after the failure to obtain the antigen with native HA characteristics in the early 1980’s, there are increasing data on successful production of HA proteins in bacteria. The vast majority of bacterial HAs have been based on the HA1 subunit of HA expressed separately or as a component of conjugate vaccines, but those based on the ectodomain and the HA2 subunit have also been reported. The most of HAs have been efficiently expressed as insoluble aggregates called inclusion bodies. Refolded and purified proteins were extensively studied for structure, the ability to bind to sialic acid-containing receptors, antigenicity, immunogenicity and efficacy. The results from these studies contradict the view that glycosylation determines the correct structure of the hemagglutinin, as they proved that bacterial HAs can be valuable vaccine antigens when appropriate folding and purification methods are applied to rationally designed proteins. The best evidence for success in bacterial production of protective HA is that vaccines based on proprietary Toll-like Receptor (VaxInnate) and bacteriophage Qβ-VLPs (Cytos Biotechnology) technologies have been advanced to clinical studies.
Źródło:
Acta Biochimica Polonica; 2014, 61, 3; 561-572
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax
Autorzy:
Żakowska, D.
Graniak, G.
Rutyna, P.
Naylor, K.
Glowacka, P.
Niemcewicz, M.
Powiązania:
https://bibliotekanauki.pl/articles/2085049.pdf
Data publikacji:
2019
Wydawca:
Instytut Medycyny Wsi
Tematy:
Bacillus anthracis
cloning pag gene
domain 4
protective antigen
protein
recombinant
vaccine
Opis:
Existing research for using the protective antigen (PA) of Bacillus anthracis as a vaccine component shows that protection against anthrax may be obtained using fragments of this protein. The aim of the research is to check whether the selected protein fragment of the protective antigen (domain 4) encoded by an appropriate nucleotide sequence of gene pag of B. anthracis, was expressed in the bacterial system of E. coli. In order to examine the selected sequence of the pag gene, a PCR reaction and a highly effective TOPO cloning strategy were used, followed by purification of the recombinant proteins and their detection by a western-blot method. In the planning of the PA4 antigen expression a higher level of effectiveness in production of small protein – domain 4 – was anticipated. As a result, the 139 amino acids protein fragment of B. anthracis PA (domain 4) was isolated. The research may have found the basis for in vivo research aimed at finding potential anthrax vaccine components.
Źródło:
Annals of Agricultural and Environmental Medicine; 2019, 26, 3; 392-395
1232-1966
Pojawia się w:
Annals of Agricultural and Environmental Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-14 z 14

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies